A Survey of Women Who Cryopreserved Oocytes for Non-medical Indications (Social Fertility Preservation).
Ayse SeyhanOznur Dundar AkinSinem ErtaşBaris AtaKayhan YakinBulent UrmanPublished in: Reproductive sciences (Thousand Oaks, Calif.) (2021)
To evaluate the expectations, experiences, and fertility awareness status of women who underwent social oocyte cryopreservation. Cohort survey study was conducted at an academic medical center. All women who underwent social oocyte cryopreservation between January 2015 and June 2016 were recruited. One hundred thirty-three women were contacted by phone to participate in a survey. The questionnaire investigated the initial motivation towards freezing, intentions to use cryopreserved oocytes, treatment experience, awareness of fertility and knowledge about chances of having a live birth with their frozen oocytes. The mean age at the time of oocyte freezing was 38.5 ± 2.68 years. The average number of mature oocytes cryopreserved was 5.48 ± 6.6 (1-16). Two major motivations were absence of a male partner (40%) and an anticipated age-related fertility decline (42%). Almost 60% overestimated the chances of natural conception, as well as the success of IVF at the age of 40 years. Half of the oocyte bankers reported that fertility declined between ages 35 and 39, but only 28% of patients estimated the live birth rate per cryopreserved oocyte correctly. Overall 98.8% stated that they would recommend oocyte cryopresevation to a friend, and 72% felt more secure in terms of reproductive potential. Despite comprehensive personalized counseling prior to the start of ovarian stimulation, many women do not seem to have a realistic understanding of reproductive aging. Even though gamete cryopreservation provides some insurance, overestimating the effectiveness of oocyte cryopreservation can also lead to a false sense of security. Clinical Trial Registration: 2016.086.IRB1.006.
Keyphrases
- pregnancy outcomes
- polycystic ovary syndrome
- healthcare
- clinical trial
- mental health
- cervical cancer screening
- breast cancer risk
- randomized controlled trial
- systematic review
- end stage renal disease
- newly diagnosed
- cord blood
- umbilical cord
- gestational age
- peritoneal dialysis
- phase ii
- mass spectrometry
- bone marrow
- open label
- mesenchymal stem cells
- smoking cessation
- skeletal muscle
- patient reported outcomes
- climate change